Lineage, Inc. Common Stock (LINE)vsStryker Corporation (SYK)
LINE
Lineage, Inc. Common Stock
$39.96
-0.03%
REAL ESTATE · Cap: $10.02B
SYK
Stryker Corporation
$285.47
-2.98%
HEALTHCARE · Cap: $112.69B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 371% more annual revenue ($25.27B vs $5.36B). SYK leads profitability with a 13.2% profit margin vs -2.7%. SYK earns a higher WallStSmart Score of 59/100 (C).
LINE
Hold39
out of 100
Grade: F
SYK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+75.9%
Fair Value
$161.27
Current Price
$39.96
$121.31 discount
Margin of Safety
-7.6%
Fair Value
$265.38
Current Price
$285.47
$20.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Areas to Watch
0.4% revenue growth
0.0% earnings growth
Operating margin of 3.3%
ROE of -1.8% — below average capital efficiency
Premium valuation, high expectations priced in
2.6% revenue growth
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap. PEG of 1.39 suggests the stock is reasonably priced for its growth.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.
SYK is growing revenue faster at 2.6% — sustainability is the question.
SYK generates stronger free cash flow (415M), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SYK scores higher overall (59/100 vs 39/100). LINE offers better value entry with a 75.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm focused on regenerative medicine, specifically developing cutting-edge cell therapy solutions for treating debilitating conditions, including ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust network of strategic collaborations, Lineage is poised to transform patient care through innovative therapeutic interventions. The company's commitment to advancing its diverse product pipeline and expediting clinical research positions it as an attractive investment opportunity for institutional investors seeking to engage in the forefront of healthcare advancements.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?